Aclaris Therapeutics, Inc. (LON:0H8T)
London
· Delayed Price · Currency is GBP · Price in USD 1.270
+0.031 (2.49%)
At close: May 16, 2025
Aclaris Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 17.78 | 18.72 | 31.25 | 29.5 | 6.64 | 6.48 | Upgrade
|
| Other Revenue | - | - | - | 0.26 | 0.12 | 0.01 | Upgrade
|
| Revenue | 17.78 | 18.72 | 31.25 | 29.75 | 6.76 | 6.48 | Upgrade
|
| Revenue Growth (YoY) | -42.87% | -40.09% | 5.03% | 340.05% | 4.30% | 53.35% | Upgrade
|
| Cost of Revenue | 50.46 | 49.04 | 114.25 | 89.77 | 48.53 | 34.47 | Upgrade
|
| Gross Profit | -32.68 | -30.32 | -83 | -60.02 | -41.77 | -27.99 | Upgrade
|
| Selling, General & Admin | 21.5 | 22.2 | 31.51 | 25.13 | 23.62 | 20.53 | Upgrade
|
| Operating Expenses | 21.5 | 22.2 | 31.51 | 25.13 | 23.62 | 20.53 | Upgrade
|
| Operating Income | -54.18 | -52.53 | -114.51 | -85.15 | -65.38 | -48.52 | Upgrade
|
| Interest & Investment Income | 8.13 | 7.95 | 8.51 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.75 | 1.91 | - | 2.95 | -1.14 | -0.42 | Upgrade
|
| EBT Excluding Unusual Items | -43.3 | -42.66 | -106 | -82.21 | -66.53 | -48.94 | Upgrade
|
| Merger & Restructuring Charges | - | - | -3.12 | - | - | - | Upgrade
|
| Other Unusual Items | - | -2.5 | 26.9 | -4.7 | -24.34 | -2.39 | Upgrade
|
| Pretax Income | -130.21 | -132.07 | -88.85 | -86.91 | -90.87 | -51.34 | Upgrade
|
| Income Tax Expense | - | - | -0.37 | - | - | -0.18 | Upgrade
|
| Earnings From Continuing Operations | -130.21 | -132.07 | -88.48 | -86.91 | -90.87 | -51.15 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | 0.14 | Upgrade
|
| Net Income | -130.21 | -132.07 | -88.48 | -86.91 | -90.87 | -51.02 | Upgrade
|
| Net Income to Common | -130.21 | -132.07 | -88.48 | -86.91 | -90.87 | -51.02 | Upgrade
|
| Shares Outstanding (Basic) | 90 | 77 | 70 | 65 | 57 | 43 | Upgrade
|
| Shares Outstanding (Diluted) | 90 | 77 | 70 | 65 | 57 | 43 | Upgrade
|
| Shares Change (YoY) | 27.19% | 10.73% | 7.05% | 14.95% | 33.36% | 2.94% | Upgrade
|
| EPS (Basic) | -1.44 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | Upgrade
|
| EPS (Diluted) | -1.45 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | Upgrade
|
| Free Cash Flow | - | -20.2 | -79.63 | -68.17 | -52.44 | -39.09 | Upgrade
|
| Free Cash Flow Per Share | - | -0.26 | -1.14 | -1.04 | -0.92 | -0.92 | Upgrade
|
| Gross Margin | -183.84% | -161.99% | -265.60% | -201.74% | - | - | Upgrade
|
| Operating Margin | -304.78% | -280.59% | -366.44% | -286.21% | -967.08% | -748.52% | Upgrade
|
| Profit Margin | -732.46% | -705.48% | -283.15% | -292.11% | -1343.96% | -787.03% | Upgrade
|
| Free Cash Flow Margin | - | -107.89% | -254.84% | -229.13% | -775.65% | -602.99% | Upgrade
|
| EBITDA | -53.94 | -52.22 | -114.45 | - | -65.06 | -48.2 | Upgrade
|
| EBITDA Margin | - | -278.95% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.24 | 0.31 | 0.06 | - | 0.32 | 0.32 | Upgrade
|
| EBIT | -54.18 | -52.53 | -114.51 | -85.15 | -65.38 | -48.52 | Upgrade
|
| EBIT Margin | - | -280.59% | - | -286.21% | - | - | Upgrade
|
| Revenue as Reported | 17.78 | 18.72 | 31.25 | 29.75 | 6.76 | 6.48 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.